Alpha Tech Est. is a distributor of medical equipment to maternity clinics, hospitals and health centers and thus already has customer contacts established in Calmark’s target group.  The distributor agreement grants Alpha Tech exclusive rights to sell and market the Calmark Neo platform in Jordan.

Calmark's reader will initially be installed at two units in the market in order to obtain clinical data in view of the registration process. The next step is to register the product with the appropriate authorities, and Alpha Tech intends to deal with this promptly. In parallel to the registration process, the focus is to train the staff and market the Neo platform and the surrounding concept to key customers in the region.

"The Middle East is a key market for Calmark," says Magdalena Tharaldsen, Calmark's Director International Business Development. "It is gratifying that we now have a partner with extensive experience of our customer segment to help us with documentation, registration, publicity and customer canvassing".

"The attention and interest we received at the Arab Health fair in Dubai showed that there is a great demand for our product in the region," says Anna Söderlund, CEO of Calmark. "Understandably, the pandemic has caused a certain delay in the marketing of new products to the healthcare sector. We are delighted to announce today's agreement, which will be the first of several in this priority region." 

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 9 September 2020, 13:15 CEST.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.